A longitudinal VBM study monitoring treatment with erythropoietin in patients with Friedreich ataxia

BACKGROUND: Recombinant human erythropoietin (rhuEPO) has received considerable attention because of its neuroprotective properties. It has recently been reported that rhuEPO increases frataxin levels in combination with clinical improvement in rhuEPO treated patients with Friedreich ataxia (FRDA)....

Descripción completa

Detalles Bibliográficos
Autores principales: Santner, Wolfram, Schocke, Michael, Boesch, Sylvia, Nachbauer, Wolfgang, Egger, Karl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184378/
https://www.ncbi.nlm.nih.gov/pubmed/25298866
http://dx.doi.org/10.1177/2047981614531573

Ejemplares similares

Ejemplares similares